Cadila Healthcare receives 3 New Product Approvals USFDA

Cadila Healthcare Ltd has announced that the Company has received three product approvals from the USFDA in quick succession. The group has received approvals to market Benzonatate Tablets 100 and 200 mg, Naproxen Tablets and tentative approval for Amlodipine Besylate Tablets 2.5, 5 and 10mg.

The branded sales in the US market of Benzonatate Tablets, which fails in the cough- suppresant segment, was estimated at USD 134 million in 2006 as per NDC. The branded sales of Amlodipine Besylate Tablets, an anti-hypertensive, was estimated at USD 2.74 billion in 2006 and that of Naproxen Tablets, which falls in the analgesic segment, was estimated at USD 0.67 billion in 2006 as per NDC Health.

The group will market all three drugs through its US subsidiary Zydus Pharmaceuticals (USA) Inc. The group now has 27 approvals since the commencement of filing process in FY 2003-04. So far, the group has filed 60 ANDAs and 51 DMFs.

The stock was trading at Rs.337.65, up by Rs.0.35 or 0.10%. The stock hit an intraday high of Rs.340 and low of Rs.333. The total traded quantity was 3486 compared to 2 week average of 13486.

Source : Equity Bulls

Keywords